Telomir Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Telomir Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Telomir Pharmaceuticals, Inc. made a loss over the last year. Telomir Pharmaceuticals, Inc. owes $0.06 for every $1 it owns. Telomir Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTelomir Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
14.77The share price is 14.77 times Telomir Pharmaceuticals, Inc.'s book value per share, higher than 90% of Healthcare companies in United States.
Market cap
$74 MThe total market value of all of Telomir Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 69% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$5 MWhat Telomir Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.07Net worth divided by the number of shares. The share price of $1.01 is 14.8 times this, which is the P/B above.
Return on equity (ROE)
-213.1%Telomir Pharmaceuticals, Inc. lost 213.1% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
Owes vs Owns
0.06×Telomir Pharmaceuticals, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Dividend yield
NoneTelomir Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossTelomir Pharmaceuticals, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Telomir Pharmaceuticals, Inc.: $74 M ÷ $5 M (30 Jun 2026) = 14.8.
What is Telomir Pharmaceuticals, Inc.'s return on equity?
Telomir Pharmaceuticals, Inc. lost 213.1% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
How much does Telomir Pharmaceuticals, Inc. owe compared with what it owns?
Telomir Pharmaceuticals, Inc. owes $0.06 for every $1 it owns (low), lower than 94% of Healthcare companies in United States.
Does Telomir Pharmaceuticals, Inc. pay a dividend?
No. Telomir Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.